VolitionRx posts corporate deck outlining Nu.Q licensing strategy across cancer, sepsis and veterinary testing
VNRX•Nu.Q licensing strategy and revenue model
VolitionRx outlined a partnership-led strategy to monetize its Nu.Q platform through licensing, milestones, component sales and royalties.
It highlighted $23 million in licensing to date and revenue of $1 million in Q1 2026.
Potential milestone and near-term catalysts
The company flagged a potential $5 million contractual milestone tied to feline use, contingent on publication of a submitted cat paper.
It targeted multiple human-space licensing deals in 2026, with confidential talks involving more than a dozen diagnostics or liquid biopsy groups.
Near-term clinical catalysts include DETECSEPs first patient expected in Q3, reimbursement submission preparation and initial EU sepsis sales.
